Remodeling of lipid metabolism orchestrates human adipose-derived mesenchymal stem cells osteodifferentiation.
Bispo DSC., Haggarty JH., Graça I., Goodfellow BJ., Rodrigues J., Mano JF.
Laboratory Study, published in Biochim Biophys Acta Mol Cell Biol Lipids (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Biochim Biophys Acta Mol Cell Biol Lipids (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42567438
- DOI
- 10.1016/j.bbalip.2026.159765
Abstract (original English)
Mesenchymal stem cell (MSC) osteodifferentiation involves adaptations of lipid metabolism but the specific regulatory roles of lipid species remain underexplored. We use a global metabolomics approach, comprising LC-MS lipidomics and NMR metabotolomics, to identify mechanistic features of human adipose-derived MSC (hAMSC) osteodifferentiation and new markers of osteogenic progression. Results show that, upon differentiation, cellular metabolism progresses through an early osteocommitment phase (day 7) followed by active osteodifferentiation (day 21), with underlying proliferation contributing towards membrane remodeling, oxidative stress protection and lipid-supported energy/signaling processes. At day 7, differentiating cells exhibit coordinated lipid remodeling and activation of the phosphocreatine (PCr)-creatine (Cr) axis. This leads to accumulation of phosphocholine, PCr and sphingomyelin, in preparation for mineralization and extracellular vesicle formation. Concomitantly, calcium oscillatory signaling and active purinergic metabolism are predicted. Other early features persist until day 21, including increased polyunsaturated fatty acids (PUFAs)-rich plasmalogen levels, enhanced endogenous substrate mobilization and metabolic autonomy. At this later stage, accumulation of storage lipids occurs, likely contributing to ω-3/ω-6 balance. FA regulation seems to be accompanied
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.